STOCK TITAN

Fortrea (FTRE) Form 144 Filed for 3,155 Shares After Vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Fortrea Holdings Inc. (FTRE) Form 144 notice shows a proposed sale of 3,155 common shares, with an aggregate market value of $32,272.81, to be sold on 09/09/2025 on NASDAQ. The shares were acquired on 09/08/2025 through restricted stock vesting and are labeled as compensation. The filer also reported a prior sale on 08/19/2025 of 4,886 shares for gross proceeds of $39,160.31. The filing includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

  • Timely disclosure of proposed insider sale under Rule 144 provides transparency to the market
  • Shares originated from restricted stock vesting, indicating the sale relates to compensation rather than external financing

Negative

  • Insider selling (proposed sale and recent prior sale) could be perceived negatively by some investors
  • Filing lacks detailed filer CIK/identity fields in the provided content, limiting full traceability within this document

Insights

TL;DR: Insider plans to sell vested compensation shares; amounts are small relative to shares outstanding, so likely limited market impact.

The filer intends to sell 3,155 shares acquired via restricted stock vesting a day earlier, representing a routine monetization of compensation rather than a company fundraising event. With 90.8 million shares outstanding, the proposed sale equals roughly 0.0035% of the float, implying minimal direct dilution or market pressure. The recent prior sale of 4,886 shares for $39,160.31 shows ongoing disposition of insider-held shares. For investors, these transactions are transparency events; they provide data on insider liquidity but do not, by size alone, signal material change to the company's capital structure.

TL;DR: Filing follows Rule 144 protocol; timely disclosure of vested shares is consistent with compliance expectations.

The Form 144 supplies required information: acquisition date, nature (restricted stock vesting), planned sale date, broker, and past three-month sales. The representation regarding absence of undisclosed material information and the signature requirement address compliance risk. The transactions appear to be routine insider liquidity from compensation, not indicative of unusual governance events such as departures or related-party transactions. Documentation is adequate for regulator and investor scrutiny.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many FTRE shares are proposed for sale in this Form 144?

The filing shows a proposed sale of 3,155 common shares with aggregate market value of $32,272.81.

When were the shares acquired and what was the acquisition type?

The shares were acquired on 09/08/2025 through restricted stock vesting and characterized as compensation.

On which exchange and what is the planned sale date for the FTRE shares?

The planned sale is on 09/09/2025 on NASDAQ.

Has the filer sold any FTRE shares in the past three months?

Yes. A prior sale on 08/19/2025 of 4,886 shares generated gross proceeds of $39,160.31.

How large are these sales relative to shares outstanding?

The issuer has 90,800,000 shares outstanding; the proposed 3,155-share sale is a very small fraction of that total.
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

FTRE Latest News

FTRE Latest SEC Filings

FTRE Stock Data

904.60M
91.88M
0.5%
111.46%
11.57%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM